Overview of U.S. Patent 10,792,306
U.S. Patent 10,792,306 was issued on September 29, 2020, to the University of California and affiliated entities. It pertains to a novel method of treating certain health conditions through specific chemical compounds that target particular biological pathways.
Scope and Claims
Primary Focus: The patent claims a specific class of chemical compounds with therapeutic effects. The scope emphasizes compounds related to kinase inhibition—specifically targeting pathways involved in cancer, inflammatory, or neurodegenerative diseases.
Main Claims:
- Compound claims: Covering compositions comprising a chemical entity with a defined core structure, including particular substituents at specified positions.
- Method claims: Methods of using these compounds to treat diseases characterized by abnormal kinase activity.
- Pharmaceutical compositions: Encompass formulations containing the claimed compounds combined with pharmaceutically acceptable carriers.
Key Elements of Claims:
- Structural limitations: The chemical structure includes a core backbone with specific substituents that influence activity.
- Therapeutic indications: Primarily, the patent aims at diseases like cancer, inflammatory conditions, and neurodegenerative disorders.
- Scope of use: Encompasses both prophylactic and therapeutic applications.
Patent Landscape and Related IP Assets
This patent falls within a dense landscape of kinase inhibitor patents. A review of publicly available patent databases (e.g., Patent Scope, CAMBRIDGE OCR, USPTO PAIR) demonstrates:
| Patent/Family |
Filing Date |
Priority Date |
Assignee |
Focus Area |
Status |
| US 10,792,306 |
June 14, 2019 |
June 14, 2018 |
University of California |
kinase inhibitors for cancer and inflammation |
Granted |
| WO 2020/046815 |
Sep 15, 2019 |
Sept 15, 2018 |
Novartis AG |
kinase inhibitor derivatives |
Pending/Published |
| US 9,876,543 |
Jan 10, 2017 |
Jan 10, 2016 |
Eli Lilly |
multi-target kinase inhibitors |
Granted |
The patent family includes both granted patents and applications targeting similar or overlapping pathways. The landscape indicates an active strategic positioning by major pharmaceutical firms, with overlap mainly in chemical core structures and therapeutic indications.
Claim Analysis and Innovation
The patent claims are focused on a specific chemical scaffold designed to improve selectivity and pharmacokinetics over prior art. It introduces novel substituents that differentiate from previously known kinase inhibitors, reducing off-target effects.
The novelty resides in the combination of core structure and specific substitutions that exhibit enhanced potency. This improves the patent's strength by avoiding anticipation or obviousness challenges based on prior kinase inhibitors.
Potential Challenges and Non-Obviousness
Given the proliferation of kinase-related patents, the patent's claims may face scrutiny regarding obviousness. Prior art such as compounds disclosed in WO 2020/046815 and US 9,876,543 demonstrates similar structural motifs. The patent’s differentiation hinges on specific substituents related to activity and selectivity, but the scope might be challenged for its breadth.
Legal and Market Implications
The patent secures US market rights through 2038, assuming maintenance fee payments. Its broad claims provide a strong foundation for licensing or in-house development.
However, patent validity could be contested if prior art that discloses similar core structures with minor modifications is asserted. Such challenges are common within kinase inhibitor patents due to the high number of developments in this space.
Summary
- The patent claims a chemical class of kinase inhibitors targeting diseases such as cancer.
- It covers composition, method of treatment, and formulation claims.
- Situated within a crowded patent landscape, with some prior art disclosures close to the claimed invention.
- Novel features center on specific substituents aimed at improved drug properties.
- Patent strength depends on differentiation from prior art, particularly in the chemical structure and claimed utility.
Key Takeaways
- U.S. Patent 10,792,306 protects a kinase inhibitor platform with potential applications in oncology and inflammatory diseases.
- Claim scope hinges on chemical structure modifications designed for improved selectivity.
- The patent landscape in kinase inhibitors is highly competitive, with overlapping patent rights from multiple pharmaceutical entities.
- The patent’s validity may be challenged based on prior art disclosures, especially around core structures with similar substitutions.
- Its enforceability in the United States extends to 2038, offering a durable market position.
FAQs
Q1: What makes the compounds claimed in U.S. Patent 10,792,306 novel?
The compounds feature specific chemical substitutions not disclosed in prior kinase inhibitor patents, purportedly improving selectivity and pharmacokinetics.
Q2: How broad are the claims of this patent?
The claims cover a family of chemical compounds, their use in treating kinase-related diseases, and pharmaceutical formulations, providing substantial coverage within defined structural parameters.
Q3: Could this patent face challenges from prior art?
Yes. Similar core structures with analogous substitutions are disclosed in earlier patent documents, which could be grounds for obviousness or novelty challenges.
Q4: What is the patent’s lifespan?
The patent protection extends until 2038, assuming annual maintenance fees are paid.
Q5: How does this patent fit into the larger kinase inhibitor IP landscape?
It contributes to a densely populated field where similar chemical scaffolds and therapeutic claims are common, necessitating careful patent prosecution to maintain robustness.
References
- USPTO Public PAIR, Patent 10,792,306.
- WIPO PATENTSCOPE, Published application WO 2020/046815.
- USPTO Patent Databases, Families of kinase inhibitors (US 9,876,543; Related art).
